AcouSort presents at Stora Aktiedagen in Stockholm, November 30, addressing current developments in the vibrant cell therapy space
On November 30, 2022, CEO Torsten Freltoft will present at Stora Aktiedagen in Stockholm. In his presentation, Torsten will talk about the company's continuous advancements in the cell therapy space, an area with potential to have a huge impact on future medical treatments. The company recently entered a collaboration with a global life science company active in the cell therapy field.
AcouSort invites journalists, analysts, and shareholders to take part in the live broadcast at www.aktiespararna.se/tv/live. No registration is required to follow the event digitally. You can also use this opportunity to ask your questions to Torsten Freltoft, by sending an SMS to 079 347 98 45 or in Aktiespararna’s live chat, which you will find in direct connection to the live player.
When: Wednesday November 30, 2022, at 7.30 pm
Where: Hotel Birger Jarl, Tulegatan 8, Stockholm, Sweden
Live broadcast: www.aktiespararna.se/tv/live
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.